Trials / Terminated
TerminatedNCT02335814
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- RAPT Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or refractory AML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FLX925 |
Timeline
- Start date
- 2015-04-08
- Primary completion
- 2017-05-03
- Completion
- 2017-05-03
- First posted
- 2015-01-12
- Last updated
- 2018-02-09
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02335814. Inclusion in this directory is not an endorsement.